New Coagulation Factor VIIa (Recombinant) Shows Dose Response and is Well Tolerated in Patients with Hemophilia A and B (with or without inhibitors). Multicenter Study Results Presented at ISTH
FRAMINGHAM, Mass, July 1, 2013 —rEVO Biologics, an LFB company, announced positive preliminary results of a key dose ranging study, which demonstrates that LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), is biologically active and well tolerated in patients with congenital hemophilia A or B at the three dosages tested.